Evidence map›Paper›PMID 27156071›Full record

ArticlePathology oncology research : POR2016

Influence of Exposure to Chronic Persistent Low-Dose Ionizing Radiation on the Tumor Biology of Clear-Cell Renal-Cell Carcinoma. An Immunohistochemical and Morphometric Study of Angiogenesis and Vascular Related Factors.

Amparo Ruiz-Saurí, Gerardo Valencia-Villa, Alina Romanenko, Jesús Pérez, Raúl García, Heydi García, José Benavent, María Sancho-Tello, Carmen Carda, Antonio Llombart-Bosch

Abstract read
PubMed Publisher
In one paragraph

Article in Pathology oncology research : POR, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 3 countries.

Amparo Ruiz-SauríDepartment of Pathology, University of Valencia, Avenida Blasco Ibañez, 15, 46010, Valencia, Spain. Amparo.Ruiz-Sauri@uv.es.
Gerardo Valencia-VillaDepartment of Pathology, University of Valencia, Avenida Blasco Ibañez, 15, 46010, Valencia, Spain.
Alina RomanenkoDepartment of Pathology, Institute of Urology, Academy of Medical Sciences of Ukraine, Kiev, Ukraine.
Jesús PérezMedical School, Universidad Libre, Barranquilla, Colombia.
Raúl GarcíaUniversidad del Norte, Medical School, Barranquilla, Colombia.
Heydi GarcíaDepartment of legal medicine, Barranquilla, Colombia.
José BenaventDepartment of Pathology, University of Valencia, Avenida Blasco Ibañez, 15, 46010, Valencia, Spain.
María Sancho-TelloDepartment of Pathology, University of Valencia, Avenida Blasco Ibañez, 15, 46010, Valencia, Spain.
Carmen CardaDepartment of Pathology, University of Valencia, Avenida Blasco Ibañez, 15, 46010, Valencia, Spain.
Antonio Llombart-BoschDepartment of Pathology, University of Valencia, Avenida Blasco Ibañez, 15, 46010, Valencia, Spain.
Universitat de València · ESINCLIVA Health Research Institute · ESBiomedical Research Networking Center in Bioengineering, Biomaterials and Nanomedicine · ESInstitute of Urology of the National Academy of Medical Sciences of Ukraine · UAUniversidad del Norte · COUniversidad Libre de Colombia · CO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Increased angiogenesis is related to boosted growth and malignancy in carcinomas. "Chronic Persistent Low-Dose Ionizing Radiation" (CPLDIR) exposure increases incidence and aggressive behavior of clear-cell renal-cell carcinoma (CCRCC). The aim was to study the biology of angiogenesis, including microvessel density (MVD), in human clear-cell renal-cell carcinomas (CCRCC) originating from a radio-contaminated geographical area (Ukraine) and to compare with similar tumors diagnosed in non-contaminated regions of Europe (Spain, Valencia) and Latin America (Colombia, Barranquilla). MVD was comparatively examined in 124 patients diagnosed with CCRCC from three geographical areas by means of digital micro-imaging and computerized analysis. Additionally, 50 adult normal kidneys were used for controls (autopsy kidneys from Valencia and Barranquilla). Furthermore, an immunohistochemical study of several vascular related growth factors was undertaken using a similar methodology. MVD as well as VEFG are the most discriminating factors associated with an aggressive behavior of CCRCC. Their expression increased in proportion to the level of exposure to chronic low-dose ionizing radiation in Ukrainian patients in the 25 years since the Chernobyl accident substantiated by comparison with the two control groups of renal carcinomas present in non-irradiated areas (Spain and Colombia). No major biological differences relating to angiogenesis appear to exist between the CCRCC diagnosed in two distant geographical areas of the world. HIF-1α expression was similar in all groups, with no statistical significance. Present findings demonstrate the existence of a significant relationship between MVD and VEGF in CCRCC: an increased expression of VEGF is associated with a high level of angiogenesis.

Indexed as

Carcinoma, Renal CellFemaleHumansHypoxia-Inducible Factor 1, alpha SubunitIntercellular Signaling Peptides and ProteinsKidney NeoplasmsMaleMiddle AgedNeovascularization, PathologicPeptidesRadiation, IonizingVascular Endothelial Growth Factor AHypoxia-Inducible Factor 1, alpha SubunitIntercellular Signaling Peptides and ProteinsPeptidesVascular Endothelial Growth Factor Avascular factorAngiogenesisAngiogenic factorsChronic persistent low-dose ionizing radiation (CPLDIR)Clear-cell renal-cell carcinoma (CCRCC)ImmunohistochemistryMicrovessel density (MVD)Morphometry

Identifiers

PMID27156071
OpenAlexW2346299626

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.